Core Insights - ReShape Lifesciences is hosting its inaugural Lap-Band® Surgeon Summit from August 1-3, 2025, in Nashville, Tennessee, directed by Dr. Christine Ren-Fielding, a leading expert in bariatric surgery [1][2] - The Summit aims to enhance collaboration with top Lap-Band® surgeons to improve patient outcomes and expand access to the Lap-Band® system, including the new Lap-Band® 2.0 FLEX [2][3] Company Overview - ReShape Lifesciences is a premier company in weight loss and metabolic health solutions, offering a range of products including the FDA-approved Lap-Band® System, which provides a minimally invasive treatment for obesity [4] - The company also has investigational products like the Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system for type 2 diabetes and the Obalon® balloon technology for non-surgical weight loss [4] Product Focus - The Summit will discuss the benefits of the original Lap-Band® and the next-generation Lap-Band® 2.0 FLEX, emphasizing the integration of GLP-1 medications in patient care and strategies for patient education [2][3] - Early feedback from the limited U.S. market release of the Lap-Band® 2.0 FLEX has been overwhelmingly positive, indicating strong market interest and potential for growth [2]

Core Points - ReShape Lifesciences Inc. has regained compliance with Nasdaq's stockholders equity requirement, closing the listing matter [1][2] - The company previously faced potential delisting due to non-compliance with the minimum stockholders' equity requirement of $2.5 million [2] - As of March 31, 2025, the company's stockholders' equity was reported at $1.2 million [3] - The company raised a total of approximately $6.3 million through the sale of common stock in June 2025, which helped it regain compliance [3] Company Overview - ReShape Lifesciences is a leading company in weight loss and metabolic health solutions, offering a range of products and services for obesity and metabolic disease management [4] - The company provides the FDA-approved Lap-Band® System, which is a minimally invasive treatment for obesity [4] - Other offerings include an investigational vagal neuromodulation system for type 2 diabetes and metabolic disorders, and the non-surgical Obalon® balloon technology for weight loss [4]

Core Viewpoint - ReShape Lifesciences has announced a public offering of 1,054,604 shares of common stock at a price of $2.50 per share, expecting gross proceeds of approximately $2.6 million before expenses [1]. Group 1: Offering Details - The public offering is being conducted under an effective shelf registration statement filed with the SEC, which was declared effective on May 14, 2025 [3]. - Maxim Group LLC is acting as the sole placement agent for this offering [2]. - The offering is expected to close on or about June 9, 2025, pending customary closing conditions [1]. Group 2: Company Overview - ReShape Lifesciences is a leading company in weight loss and metabolic health solutions, offering a range of products and services for obesity and metabolic disease management [4]. - The company’s FDA-approved products include the Lap-Band® systems, which provide minimally invasive treatment options for obesity, and the ReShape Diabetes Neuromodulation system, which targets glucose regulation [4]. - The Obalon® balloon technology is another innovative product that offers a non-surgical method for weight loss [4].